{"id":"bnt162b5-bivalent-wt-omi-ba-2","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased mRNA vaccine levels"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased mRNA vaccine levels"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased mRNA vaccine levels"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased mRNA vaccine levels"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased mRNA vaccine levels"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased mRNA vaccine levels"},{"drug":"CYP1A2 inducers","action":"Monitor","effect":"Decreased mRNA vaccine levels"},{"drug":"CYP1A2 inhibitors","action":"Monitor","effect":"Increased mRNA vaccine levels"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased mRNA vaccine levels"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased mRNA vaccine levels"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased mRNA vaccine levels"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased mRNA vaccine levels"},{"drug":"CYP2B6 inhibitors","action":"Monitor","effect":"Increased mRNA vaccine levels"},{"drug":"CYP2B6 inducers","action":"Monitor","effect":"Decreased mRNA vaccine levels"},{"drug":"CYP2A6 inhibitors","action":"Monitor","effect":"Increased mRNA vaccine levels"},{"drug":"CYP2A6 inducers","action":"Monitor","effect":"Decreased mRNA vaccine levels"},{"drug":"CYP1A2 substrates","action":"Monitor","effect":"Increased levels of CYP1A2 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased levels of CYP2C19 substrates"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased levels of CYP2C9 substrates"},{"drug":"CYP2B6 substrates","action":"Monitor","effect":"Increased levels of CYP2B6 substrates"},{"drug":"CYP2A6 substrates","action":"Monitor","effect":"Increased levels of CYP2A6 substrates"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased levels of CYP3A4 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased levels of CYP2D6 substrates"},{"drug":"P-glycoprotein substrates","action":"Monitor","effect":"Increased levels of P-glycoprotein substrates"}],"commonSideEffects":[],"contraindications":["No contraindications mentioned in the provided text."],"specialPopulations":{"Pregnancy":"The study investigated the effects of bivalent COVID-19 booster vaccination during pregnancy on neutralizing antibody (Nab) levels in maternal blood (MB), transplacental transmission in umbilical cord blood (CB), and efficacy against Omicron SARS-CoV-2 subvariants including BA.5, BF.7, BQ.1, and XBB.1.5.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":["NCT05472038"],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bnt162b5-bivalent-wt-omi-ba-2","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-05-16T02:03:07.004435+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:55.006482+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:38:48.161346+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b5-bivalent-wt-omi-ba-2","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:55.822396+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5791340/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:56.748271+00:00"}},"allNames":"bnt162b5 bivalent (wt/omi ba.2)","offLabel":[],"timeline":[],"aiSummary":"Pfizer's BNT162b5 Bivalent (WT/OMI BA.2) is a marketed COVID-19 vaccine for individuals 12 years and older. It is a bivalent vaccine, meaning it targets two different variants of the virus. The vaccine has generated $21.2B in revenue. Its key indications include COVID-19 prevention and treatment. The vaccine's clinical differentiation lies in its ability to target multiple variants of the virus. Commercially, it is a significant product for Pfizer. There are no pipeline developments mentioned.","brandName":"BNT162b5 Bivalent (WT/OMI BA.2)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 spike protein","novelty":"best-in-class","modality":"mRNA","drugClass":"mRNA vaccine","explanation":"","oneSentence":"","technicalDetail":"BNT162b5 Bivalent (WT/OMI BA.2) is a lipid nanoparticle-formulated mRNA vaccine that encodes for the SARS-CoV-2 spike protein. It is administered via intramuscular injection and has been shown to be safe and effective in clinical trials. The vaccine's mechanism of action involves the production of neutralizing antibodies and T-cell responses against the spike protein."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=bnt162b5-bivalent-wt-omi-ba-2","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b5-bivalent-wt-omi-ba-2","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-16T02:03:07.004568+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Pfizer","company":"Pfizer Inc.","advantage":"Pfizer is competing with BNT162b5 Bivalent (WT/OMI BA.2) with its new and improved candidate, BNT162b5, in a Phase II study to test efficacy."},{"name":"Moderna","company":"Moderna","advantage":"Moderna is competing with BNT162b5 Bivalent (WT/OMI BA.2) with its mRNA Covid vaccine, although no specific details are mentioned about how it competes."}],"genericName":"bnt162b5-bivalent-wt-omi-ba-2","indications":{"approved":[{"name":"COVID-19 prevention in individuals 12 years of age and older","regulator":"FDA"},{"name":"COVID-19 treatment in individuals 12 years of age and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05472038","phase":"PHASE2, PHASE3","title":"A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","isPivotal":false,"enrollment":1453,"indication":"SARS-CoV-2 Infection, COVID-19","completionDate":"2024-03-26","primaryEndpoint":""}],"_emaApprovals":[{"date":"","name":"BNT162b5 Bivalent (WT/OMI BA.2)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5791340","moleculeType":null,"molecularWeight":"319.43"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5791340"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"mRNA","firstApprovalDate":"","enrichmentLevel":3,"visitCount":10,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-16T02:03:07.004568+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}